MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$4,290,700K
Net Income
$1,249,200K
Net Profit Margin
29.11%
EPS
$12.23
Unit: Thousand (K) dollars
Revenue Breakdown
Collaboration Revenue
EYLEAHD
Eylea Net Product Sales
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenues
4,290,700
3,605,400
3,884,300
3,754,300
Research and development
1,631,600
1,543,500
1,626,100
1,475,000
Acquired in-process research and development
127,000
101,900
18,700
83,100
Selling, general, and administrative
662,100
647,700
775,000
657,800
Cost of goods sold, collaboration and contract manufacturing-Product
360,700
373,400
318,700
281,000
Cost of goods sold, collaboration and contract manufacturing-Collaborationand Contract Manufacturing
215,800
296,000
265,900
240,600
Other operating (income) expense, net
-
-
0
10,000
Total expenses
2,997,200
2,962,500
3,004,400
2,727,500
Income from operations
1,293,500
642,900
879,900
1,026,800
Other income (expense), net
245,300
201,200
176,000
755,800
Interest expense
11,000
12,900
12,200
19,300
Total other income (expense)
234,300
188,300
163,800
736,500
Income before income taxes
1,527,800
831,200
1,043,700
1,763,300
Income tax expense
230,900
104,000
199,100
303,300
Net income
1,296,900
727,200
844,600
1,460,000
Unrealized (loss) gain on debt securities
-48,000
-65,800
7,100
15,700
Gain on foreign currency translation
300
200
1,400
800
Comprehensive income
1,249,200
661,600
853,100
1,476,500
Basic EPS
12.62
6.99
8.283
14.09
Diluted EPS
12.23
6.75
7.943
13.62
Basic Average Shares
102,800,000
104,000,000
103,000,000
103,600,000
Diluted Average Shares
106,000,000
107,700,000
107,400,000
107,200,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
EYLEAHD
$596,300K
Eylea Net Product
Sales
$412,200K
(-45.35%↓ Y/Y)
US
$342,600K
(38.26%↑ Y/Y)
Non Us
$146,800K
(14.06%↑ Y/Y)
EYLEAHDAnd EYLEA-US
$1,008,500K
LIBTAYONet Product Sales
$489,400K
(29.99%↑ Y/Y)
Praluent Net Product
Sales-US
$74,700K
(13.53%↑ Y/Y)
Evkeeza-US
$53,300K
(29.37%↑ Y/Y)
Lynozyfic
$16,500K
Collaboration Revenue
$2,455,000K
(31.94%↑ Y/Y)
Product
$1,642,400K
(0.70%↑ Y/Y)
Product And Service
Other
$193,300K
(5.11%↑ Y/Y)
Revenues
$4,290,700K
(16.73%↑ Y/Y)
Other income
(expense), net
$245,300K
(-44.60%↓ Y/Y)
Income from operations
$1,293,500K
(19.82%↑ Y/Y)
Total other income
(expense)
$234,300K
(-46.65%↓ Y/Y)
Total expenses
$2,997,200K
(15.45%↑ Y/Y)
Interest expense
$11,000K
(205.56%↑ Y/Y)
Income before income
taxes
$1,527,800K
(0.60%↑ Y/Y)
Research and development
$1,631,600K
(14.76%↑ Y/Y)
Selling, general, and
administrative
$662,100K
(4.40%↑ Y/Y)
Cost of goods sold,
collaboration and contract...
$360,700K
(30.88%↑ Y/Y)
Cost of goods sold,
collaboration and contract...
$215,800K
(-15.24%↓ Y/Y)
Acquired in-process
research and development
$127,000K
(1170.00%↑ Y/Y)
Net income
$1,296,900K
(-6.81%↓ Y/Y)
Gain on foreign
currency translation
$300K
(-76.92%↓ Y/Y)
Income tax expense
$230,900K
(81.67%↑ Y/Y)
Comprehensive income
$1,249,200K
(-11.72%↓ Y/Y)
Unrealized (loss) gain on
debt securities
-$48,000K
(-317.19%↓ Y/Y)
Buy us a coffee
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)
🚨
Price Alert:
The stock price jumped by 13.38% after the earning call.